Annual results show revenue and operating profit rising together. Revenue went from KRW 1.33 trillion in 2022 to KRW 1.49 trillion in 2023 (up 12.0%), KRW 1.5 trillion in 2024 (up 0.3%) and KRW 1.55 trillion in 2025 (up 3.5%), and has risen for three consecutive years from 2023 through 2025.
Operating profit rose from KRW 158.1 billion in 2022 to KRW 220.7 billion in 2023 (up 39.6%), dipped to KRW 216.2 billion in 2024 (down 2.0%), and reached KRW 257.8 billion in 2025 (up 19.2%), the largest year of 2022 to 2025. The operating margin was 11.9% in 2022, 14.8% in 2023, 14.5% in 2024 and 16.7% in 2025.
Profit attributable to owners of the parent was KRW 82.8 billion in 2022, KRW 146.2 billion in 2023 (up 76.6%), KRW 121.3 billion in 2024 (down 17.0%) and KRW 169.6 billion in 2025 (up 39.8%).
Net profit including non-controlling interests, at KRW 187.1 billion in 2025, is a separate figure from profit attributable to owners of the parent. The debt-to-equity ratio fell from 90.7% in 2022 to 50.2% in 2025, with total equity of KRW 1.42 trillion and total liabilities of KRW 714.7 billion at the end of 2025.
Operating cash flow peaked at KRW 216.5 billion in 2023 and was KRW 173.1 billion in 2025. Quarterly results are far less even.
Operating profit was KRW 83.3 billion in the fourth quarter of 2025, KRW 53.6 billion in the first quarter of 2026 (down 35.6% from the prior quarter) and KRW 131.1 billion in the second quarter (up 144.4%).
The second-quarter figure included the one-time recognition of an upfront payment from the sonefpeglutide licensing deal, and the reversal of that base effect weighed on third-quarter operating profit of KRW 37.8 billion, down 31.3% year on year.
Profit attributable to owners of the parent was KRW 12.2 billion in the third quarter, down 69.5% from a year earlier. Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, that profit totaled KRW 189.2 billion, above the full-year 2025 figure of KRW 169.6 billion.